Founded in 1991, Albany Molecular Research, Inc. (Nasdaq: AMRI) is a
chemistry-based drug discovery, development and manufacturing company, focusing
on small molecule prescription drugs. AMRI provides chemistry expertise at all
stages of the drug discovery process (see chart below), from identifying leads
for validated targets, to lead optimization, scale-up, in vitro metabolism, and
cGMP synthesis and manufacturing for clinical trials and commercial products. To
complement these capabilities, AMRI maintains an in-house analytical chemistry
department with state-of-the-art analytical equipment.
Company research has led to dozens of issued and pending patents, including
important patents for the active ingredient in the non-sedating antihistamine,
Allegra, developed and marketed by Sanofi-Aventis. A key strategy of the company
is to develop, acquire and apply promising new technology in order to bring
added value to drug discovery and development projects.
AMRI maintains both a comprehensive chemistry services platform and a
proprietary R&D platform. Since its inception, AMRI has provided contract
chemistry services to many of the world's leading pharmaceutical and
biotechnology companies. AMRI's chemistry services platform includes medicinal
chemistry, chemical process research and development, analytical chemistry and
cGMP manufacturing. In addition, the company maintains several unique and/or
proprietary technologies, including one of the industry's largest collections of
natural products-based extracts (for lead discovery), biocatalysis, in vitro
biology and fermentation. Customers collaborate with AMRI for a number of
reasons: to complement their existing resources, to use AMRI as a chemistry
department when none exists, to access unique technologies and expertise, and
many others. For information about AMRI's chemistry services, use the following
links: discovery services, preclinical services, clinical services and
In addition to providing chemistry services, AMRI also conducts its own
proprietary research and development, with the goal of licensing preclinical and
clinical compounds to a commercialization partner. The company has internal
research programs in a number of therapeutic areas, including CNS/neurology,
oncology, immune disorders, irritable bowel disease and anti-inflammation. These
programs make use of AMRI's compound collections and expertise in high
throughput screening, medicinal chemistry, natural products chemistry and
biocatalysis. AMRI's proprietary R&D platform also includes collaborations in
which customers may access one or more of the company's unique technologies,
including natural products, high throughput screening, biocatalysis and
fermentation. Internal research programs are at various stages of development,
with several projects available for outlicensing. For more information about
AMRI's proprietary research, please visit our R&D pages.
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
In this interview, Laura-Isabelle, the Director of Sales at Photon etc., talks to AzoNano about how spectral imaging can help improve the next generation of solar cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.